Targeted Next Generation Sequencing for Molecular Diagnosis of Usher

Targeted Next Generation Sequencing for Molecular Diagnosis of Usher

Aparisi et al. Orphanet Journal of Rare Diseases 2014, 9:168 http://www.ojrd.com/content/9/1/168 RESEARCH Open Access Targeted next generation sequencing for molecular diagnosis of Usher syndrome María J Aparisi1,2, Elena Aller1,2, Carla Fuster-García1, Gema García-García1,4, Regina Rodrigo1,2, Rafael P Vázquez-Manrique1,2, Fiona Blanco-Kelly2,3, Carmen Ayuso2,3, Anne-Françoise Roux4, Teresa Jaijo1,2† and José M Millán1,2,5*† Abstract Background: Usher syndrome is an autosomal recessive disease that associates sensorineural hearing loss, retinitis pigmentosa and, in some cases, vestibular dysfunction. It is clinically and genetically heterogeneous. To date, 10 genes have been associated with the disease, making its molecular diagnosis based on Sanger sequencing, expensive and time-consuming. Consequently, the aim of the present study was to develop a molecular diagnostics method for Usher syndrome, based on targeted next generation sequencing. Methods: A custom HaloPlex panel for Illumina platforms was designed to capture all exons of the 10 known causative Usher syndrome genes (MYO7A, USH1C, CDH23, PCDH15, USH1G, CIB2, USH2A, GPR98, DFNB31 and CLRN1), the two Usher syndrome-related genes (HARS and PDZD7) and the two candidate genes VEZT and MYO15A. A cohort of 44 patients suffering from Usher syndrome was selected for this study. This cohort was divided into two groups: a test group of 11 patients with known mutations and another group of 33 patients with unknown mutations. Results: Forty USH patients were successfully sequenced, 8 USH patients from the test group and 32 patients from the group composed of USH patients without genetic diagnosis. We were able to detect biallelic mutations in one USH gene in 22 out of 32 USH patients (68.75%) and to identify 79.7% of the expected mutated alleles. Fifty-three different mutations were detected. These mutations included 21 missense, 8 nonsense, 9 frameshifts, 9 intronic mutations and 6 large rearrangements. Conclusions: Targeted next generation sequencing allowed us to detect both point mutations and large rearrangements in a single experiment, minimizing the economic cost of the study, increasing the detection ratio of the genetic cause of the disease and improving the genetic diagnosis of Usher syndrome patients. Keywords: Usher syndrome, Molecular diagnosis, Next generation sequencing, Point mutations, Large rearrangements Background USH has a remarkable clinical and genetic heterogen- Usher syndrome (USH) is an autosomal recessive disease eity. According to the severity and progression of the characterized by the association of sensorineural hearing disease, three clinical types are distinguished. Type I loss, retinitis pigmentosa (RP) and, in some cases, ves- (USH1) is defined by profound congenital hearing loss, tibular dysfunction. Its prevalence ranges from 3 to 6.2 onset of RP usually within the first decade of life and an per 100,000 [1-3] and it is the most common form of absence of vestibular function. Usher syndrome type II hereditary syndromes combining hearing loss and retin- (USH2) patients display congenital moderate-severe hear- itis pigmentosa. ing loss, onset of RP around or after puberty and normal vestibular function. Usher syndrome type III (USH3) is * Correspondence: [email protected] characterized by postlingual progressive hearing loss, RP †Equal contributors with a variable age of onset and variable vestibular re- 1 Grupo de Investigación en Enfermedades Neurosensoriales. Instituto de sponse [4]). However, in some patients the disease does Investigación Sanitaria IIS-La Fe, Semisótano Escuela de Enfermería, Hospital Universitario La Fe, Avda. Campanar, 21, 46009 Valencia, Spain not fit into any of these three subtypes, and they are classi- 2CIBER de Enfermedades Raras (CIBERER), Valencia, Spain fied as ‘atypical Usher syndrome’. Full list of author information is available at the end of the article © 2014 Aparisi et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Aparisi et al. Orphanet Journal of Rare Diseases 2014, 9:168 Page 2 of 15 http://www.ojrd.com/content/9/1/168 To date, 10 genes and three additional loci have been The USH2 protein network, localized at the periciliary associated with the disease. For USH1 six genes have ridge complex region, contributes to the trafficking of been identified: MYO7A (USH1B), USH1C (USH1C), cargos moving from the inner segment to the outer CDH23 (USH1D), PCDH15 (USH1F), USH1G (USH1G) segment of the photoreceptor cells through the connect- and CIB2 (USH1J); and two additional loci have been ing cilium. The USH1 interactome has been reported to described: USH1E [5] and USH1H [6]. Three genes have localize at the membrane-membrane connection site be- been found to cause USH2: USH2A (USH2A), GPR98 tween the outer segment of the photoreceptor cells and (USH2C) and DFNB31 (USH2D). For USH3 only muta- the calyceal processes in primates. This USH1 protein tions in CLRN1 have been described, and a second locus complex is thought to form an adhesion belt and would was proposed, USH3B. Furthermore, most of these genes contribute to the daily renewal of photoreceptors outer are also responsible for non-syndromic hearing loss or segments [22-24]. isolated RP [4,7]. Traditionally, the molecular diagnosis of Usher syn- In addition to these 10 genes, three other genes have drome has been mainly based on Sanger sequencing been associated with USH. PDZD7 was proposed as a [25,26]. However, the large size of most USH genes (above contributor of digenic inheritance with GPR98, and as a 350 exons in total) makes this technique expensive retinal disease modifier in USH2A patients [8]. Recently, and time-consuming. Array-based mutation screenings a novel biallelic missense variant in HARS was identified (arrayed primer extension (APEX) technology) have be- in two patients with a phenotype compatible with USH3. come a rapid and efficient technique to detect previously This gene encoding an aminoacyl tRNA synthetase was described mutations, and a specific APEX-microarray for proposed as a novel gene causative of USH3 [9]. More USH was developed [26]. However, most of USH muta- recently, CEP250 has been associated with atypical Usher tions are private, so the low detection rate of the APEX- syndrome [10]. microarray for Usher syndrome hampers the use of this Proteins encoded by Usher genes belong to different technology [27,28]. Furthermore, Copy Number Variants classes: actin-based motor protein, scaffolding proteins, (CNVs) have been identified as an important cause of the cell-adhesion molecules or transmembrane proteins, some disease in Usher syndrome. Deletions and duplications of them with very large extracellular domains. These are screened by Multiplex Ligation-dependent Probe proteins through their protein-protein interacting do- Amplification (MLPA), for which commercial probemix is mains are integrated in a network known as “Usher- only available for USH2A and PCDH15,orbyarray- interactome”. The main sites of colocalization of Usher Comparative Genomic Hibridization (a-CGH) [29-31]. proteins are the stereocilia or hair bundle of the inner ear In recent years, next generation sequencing (NGS) hair cells, and the synaptic and periciliary areas of the pho- techniques have been developed further, permitting the toreceptors [4,11]. whole genome, whole exome and targeted gene sequen- In the stereocilia, two different USH protein networks cing to be more feasible, and hence making the identifi- are known to be involved in the development and main- cation of diseased genes and the underlying mutations tenance of the inner ear hair cells. One of them is com- easier, rapid and cost-effective. The improvement of posed of the USH2 proteins, myosin VIIA (encoded by NGS has been especially useful in the diagnosis of genetic- MYO7A), Vezatin and PDZD7 [12,13]. Vezatin is encoded ally heterogeneous diseases, such as hearing loss or retinal by VEZT and it is required for the sound resilience of dystrophies [32-35]. cochlear hair cells. In addition, it has been proposed that For Usher syndrome, several NGS methods have been it is involved in the maturation steps of these cells or in developed. Licastro et al. [36] used two different ap- the maintenance of junction integrity between hair cells proaches: whole exome sequencing with the use of the and supporting cells in the inner ear [14]. The second ste- SOLiD system and long-PCR sequencing on nine USH reocilia interactome is composed of the USH1 proteins genes with two different platforms, Illumina (Genome [15]. In this network, several unconventional myosins, Analyzer II) and the Roche 454 (GS FLX). Recently, as myosin XVa, have also been found [16-18]. Mutations Besnard et al. [37] developed a targeted NGS approach. in MYO15A, the gene encoding Myosin XVa, are respon- They included 9 USH genes, 2 candidate USH genes sible for non-syndromic autosomal recessive hearing (VEZT and PDZD7), seven hearing-loss genes and the loss DFNB3 [19]. In addition, Myosin XVa interacts with choroideremia-causative gene CHM and the sequencing whirlin in stereocilia, considered

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    15 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us